Okinawa, Japan, long recognized as the original "Blue Zone" for its high concentration of exceptionally long-lived individuals, is at the forefront of a groundbreaking new research initiative. Klotho Neurosciences, a biogenetics company specializing in cell and gene therapies, has teamed up with the esteemed Okinawa Research Center for Longevity Science (ORCLS) to investigate the crucial role of the alpha-Klotho gene and its secreted protein isoform (s-KL) in promoting healthy aging and extending both lifespan and healthspan.

Decades of research by ORCLS, which led to the discovery of other global "longevity hotspots," have laid the foundation for this collaboration. Preliminary data from ORCLS suggests that the human alpha-Klotho gene and its s-KL protein may be key contributors to healthy longevity. As we age, levels of alpha-Klotho in our blood and tissues naturally decline, a decrease that often precedes the onset of various age-related pathologies affecting multiple organ systems. Crucially, replenishing s-KL levels through gene therapy shows promise in potentially protecting against neurodegenerative disorders, muscle and bone loss, and dysfunction in the heart, liver, and kidneys associated with aging.

KLTO and ORCLS scientists believe there's a strong correlation between maintaining optimal blood levels of the Klotho protein in later life and longevity, while lower levels are linked to premature aging and a higher risk of developing certain neurological disorders. While animal study results don't always translate directly to humans, the exceptional outcomes were highly encouraging. KLTO believes its patented s-KL protein isoform holds substantial promise for developing effective treatments not only for neurological disorders like ALS, Alzheimer's, and Parkinson's disease, but also for other age-related conditions such as sarcopenia, osteoporosis, diabetes, and various renal and cardiovascular disorders. Dr. Sinkule is confident that this collaboration with ORCLS's highly experienced team will provide critical evidence supporting the Klotho protein's role as a vital factor in sustaining human healthspan and preventing age-related diseases.

The company's portfolio includes proprietary cell and gene therapy programs utilizing DNA and RNA as therapeutics, as well as genomics-based diagnostic assays. Its leadership team and advisors bring extensive experience in biopharmaceutical product development and commercialization. This collaboration between Klotho Neurosciences and the Okinawa Research Center for Longevity Science marks a significant step forward in understanding and potentially harnessing the power of the Klotho gene to promote healthier and longer lives.